Achieve Life Sciences (ACHV) EBT Margin (2010 - 2015)

Achieve Life Sciences (ACHV) posted EBT Margin of 20.5% for Q4 2015, up 94.74% on a QoQ basis from 389.5% in Q4 2012.

Achieve Life Sciences (ACHV) EBT Margin (2010 - 2015) Analysis & Trends

Achieve Life Sciences' EBT Margin history runs 4 years deep, the most recent figure standing at 20.5% for Q4 2015.

Quarterly EBT Margin changed N/A year-over-year to 20.5% in Q4 2015, while the trailing twelve-month figure through Dec 2015 was 160.75% (changed N/A YoY) and the FY2015 annual result came in at 6.8%, changed N/A from the prior year.
EBT Margin was 20.5% for Q4 2015 at Achieve Life Sciences, up from 389.5% in the prior quarter.
Across five years, EBT Margin topped out at 346.05% in Q2 2011 and bottomed at 1600.08% in Q4 2011.
A 3-year average of 284.04% and a median of 253.96% in 2011 frame the typical range for EBT Margin.
Annual changes were most pronounced in 2011 — EBT Margin plunged 148012 bps — and 2012, when it surged 121058 bps.
Achieve Life Sciences' EBT Margin stood at 1600.08% in 2011, then soared by 76 bps to 389.5% in 2012, then surged by 95 bps to 20.5% in 2015.
Business Quant data shows ACHV's EBT Margin at 20.5% in Q4 2015, 389.5% in Q4 2012, and 90.11% in Q3 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	17.13%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	41.95%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.05%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	34.77%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Achieve Life Sciences	2.54 Mn	2.54 Mn	-	-

Download Data